格隆汇1月20日丨昭衍新药(603127.SH)公布，预计2025年实现营业收入约人民币15.73亿元到人民币 17.38亿元，与上年同期的数据相比，将减少约人民币28,019.80 万元到人民币 44,573.47 万元，同比减少 约 13.9%到 22.1%。 预计2025年实现归属于上市公司股东的净利润约人民币2.33亿元到人民币3.49亿元，与上年同期的数据 相比，将增加约人民币15,853.52万元到人民币 27,484.06万元，同比增加约214.0%到371.0%。 预计 2025 年实现归属于上市公司股东的扣除非经常性损益的净利润约人民币 24,638.00 万元到人民币 36,956.99 万元，与上年同期的数据相比，将增加约人民币 22,280.66 万元到人民币 34,599.65 万元，同 比增加约945.2%到1,467.7%。 ...

预计2025年实现归属于上市公司股东的净利润约人民币2.33亿元到人民币3.49亿元，与上年同期的数据 相比，将增加约人民币15,853.52万元到人民币 27,484.06万元，同比增加约214.0%到371.0%。 预计 2025 年实现归属于上市公司股东的扣除非经常性损益的净利润约人民币 24,638.00 万元到人民币 36,956.99 万元，与上年同期的数据相比，将增加约人民币 22,280.66 万元到人民币 34,599.65 万元，同 比增加约945.2%到1,467.7%。 格隆汇1月20日丨昭衍新药(603127.SH)公布，预计2025年实现营业收入约人民币15.73亿元到人民币 17.38亿元，与上年同期的数据相比，将减少约人民币28,019.80 万元到人民币 44,573.47 万元，同比减少 约 13.9%到 22.1%。 ...

Core Viewpoint - Zhaoyan New Drug (603127.SH) forecasts a net profit attributable to shareholders of 233 million to 349 million yuan for the fiscal year 2025, representing a year-on-year growth of 214.0% to 371.0% [1] Group 1 - The increase in profit is driven by rising market prices of biological assets and natural growth appreciation, leading to positive fair value changes [1]

Core Viewpoint - Zhaoyan New Drug (603127) expects a net profit attributable to shareholders of approximately 233 million to 349 million yuan in 2025, representing a year-on-year increase of about 214% to 371% [1] Group 1 - The increase in net profit is driven by the rise in market prices of biological assets and the natural growth appreciation of the assets [1] - The dual factors of market price increase and asset appreciation contribute positively to the company's performance [1]

Core Viewpoint - Zhaoyan New Drug has released its annual performance forecast, expecting a significant increase in net profit for 2025, driven by rising market prices of biological assets and stable laboratory operations [1] Group 1: Financial Performance - The company anticipates a net profit attributable to shareholders of approximately 232.61 million to 348.92 million yuan for 2025, representing a year-on-year increase of 214.00% to 371.00% [1] - The expected net profit after deducting non-recurring gains and losses is projected to be around 246.38 million to 369.57 million yuan, with a year-on-year growth of 945.20% to 1,467.70% [1] Group 2: Contributing Factors - The increase in fair value of biological assets is attributed to both rising market prices and natural growth, positively impacting the company's performance [1] - Despite maintaining stable operations in the laboratory, the company experienced a decline in revenue and gross margin from performance contracts due to previous intense industry competition, leading to a decrease in profit contribution from laboratory services [1]

Core Viewpoint - The company expects a significant increase in net profit attributable to shareholders for 2025, projecting between RMB 233 million and RMB 349 million, which represents a year-on-year increase of approximately 214.0% to 371.0% compared to the previous year [1] Financial Performance - The projected net profit increase is expected to be between RMB 159 million and RMB 275 million compared to the same period last year [1] - The growth in fair value is driven by a combination of rising market prices for biological assets and natural growth appreciation [1]

Group 1 - On January 16, Zhaoyan New Drug experienced a decline of 1.84% with a trading volume of 673 million yuan, and the net financing buy was -7.46 million yuan [1] - As of January 16, the total balance of margin trading for Zhaoyan New Drug was 420 million yuan, with a financing balance of 415 million yuan, accounting for 1.56% of the circulating market value, which is below the 50th percentile level over the past year [1] - The company primarily engages in non-clinical safety evaluation services for drugs, with 95.59% of its main business revenue derived from non-clinical research services [1] Group 2 - As of September 30, the number of shareholders for Zhaoyan New Drug increased by 57.61% to 96,500, while the average circulating shares per person remained at 0 [2] - For the period from January to September 2025, Zhaoyan New Drug reported an operating income of 985 million yuan, a year-on-year decrease of 26.23%, while the net profit attributable to the parent company was 80.71 million yuan, reflecting a year-on-year increase of 214.79% [2] - The company has distributed a total of 703 million yuan in dividends since its A-share listing, with 356 million yuan distributed over the past three years [3]

Core Insights - The top three companies with the highest short positions as of January 9 are Vanke Enterprises (02202), Dongfang Electric (01072), and COSCO Shipping Holdings (01919), with short ratios of 18.74%, 17.39%, and 16.49% respectively [1][2] - The companies with the largest absolute increase in short positions are Goldwind Technology (02208), Zhaoyan New Drug (06127), and Jingtai Holdings (02228), with increases of 6.84%, 2.14%, and 1.85% respectively [1][2] - The companies with the largest absolute decrease in short positions are COSCO Shipping Energy (01138), Sanhua Intelligent Control (02050), and Huahong Semiconductor (01347), with decreases of -1.77%, -0.80%, and -0.71% respectively [1][3] Top 10 Short Positions - Vanke Enterprises (02202) has a short position of 413 million shares, representing a short ratio of 18.74% [2] - Dongfang Electric (01072) has a short position of 70.93 million shares, with a short ratio of 17.39% [2] - COSCO Shipping Holdings (01919) has a short position of 475 million shares, with a short ratio of 16.49% [2] - Other notable companies in the top 10 include Heng Rui Medicine (01276) at 15.19% and Ping An Insurance (02318) at 14.74% [2] Largest Increases in Short Positions - Goldwind Technology (02208) saw its short ratio increase from 4.35% to 11.18%, an increase of 6.84% [2] - Zhaoyan New Drug (06127) increased from 6.65% to 8.79%, an increase of 2.14% [2] - Jingtai Holdings (02228) increased from 3.34% to 5.19%, an increase of 1.85% [2] Largest Decreases in Short Positions - COSCO Shipping Energy (01138) decreased from 7.11% to 5.34%, a decrease of -1.77% [3] - Sanhua Intelligent Control (02050) decreased from 6.52% to 5.72%, a decrease of -0.80% [3] - Huahong Semiconductor (01347) decreased from 4.85% to 4.13%, a decrease of -0.71% [3]

Group 1 - The healthcare services sector opened with a continuous upward trend, with Puris rising over 14% and reaching a new high during the session [1] - Meiyuan Health achieved a four-day consecutive increase, while New Mileage recorded a two-day consecutive increase [1] - International Medicine hit the daily limit, and companies such as Boteng Co., Zhaoyan New Drug, Nossger, Lanwei Medicine, and Berry Genomics also experienced gains [1]

Core Viewpoint - The healthcare sector has shown a strong upward trend in opening trading, with several companies experiencing significant gains and reaching new highs [1] Group 1: Company Performance - Puris has surged over 14% and reached an intraday high [1] - Meiyuan Health has achieved a four-day consecutive increase [1] - New Mileage has recorded a two-day consecutive increase [1] - International Medicine has hit the daily limit [1] - Boteng Co., Zhaoyan New Drug, Nossger, Lanwei Medical, and Berry Genomics have also seen upward movements [1]